08-10-2018 | Image
Table 4. Endocrine IRAEs with PD1–CTLA4 combination therapy
CTLA4, cytotoxic T-lymphocyte antigen 4; IRAEs, immune-related adverse events; NR, not reported; PD1, programmed cell death protein 1.
*Includes autoimmune thyroiditis, unspecified thyroid disorders.
‡Only concurrent combo therapy reported. Sequenced treatment arm (n = 33) was not reported.
||Percentage determined by total number of events divided from total number of patients only from studies reporting event.